Procurement Inclusion Criteria:
- Diagnosis of GPC3-positive recurrent glioblastoma with previous resection planned for repeat resection.
- Age ≥18 years
- Karnofsky score ≥60%
- Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent
- GPC3 expression (as determined by immunohistochemistry) with an extent score of ≥ Grade 2 (>25% positive tumor cells) and an intensity score of ≥ 2 (scale 0-4).
Procurement Exclusion Criteria:
- History of hypersensitivity reactions to murine protein-containing products OR presence of human anti-mouse antibody (HAMA) prior to enrollment (only patients who have received prior therapy with murine antibodies).
- History of organ transplantation
- Known HIV positivity
- Active bacterial, fungal or viral infection (except Hepatitis B or Hepatitis C virus infections).
- Exhibits other risk factors of which administration of investigational agent is deemed not in the patient's best interest, in the opinion of the investigator
Treatment Inclusion Criteria:
- Age ≥ 18 years
- Diagnosis of recurrent glioblastoma with previous resection
- Karnofsky score ≥ 60%-
- Stable neurologic exam for 7 days prior to enrollment
- Stable or decreasing dose of steroids over past 7 days prior to surgery and administration of therapy (max allowable dose is 0.1mg/kg dexamethasone or equivalent per day)
- Adequate organ function:
- Creatinine clearance as estimated by Cockcroft Gault or Schwartz ≥ 60 ml/min
- total bilirubin < 3 times ULN for age
- INR ≤1.7
- absolute neutrophil count > 500/μl
- platelet count > 100,000/μl (can be transfused but must be achieved prior to enrollment)
- Hgb ≥ 7.0 g/dl (can be transfused)
- Pulse oximetry >90% on room air
- Recovered from acute toxic effects of all prior chemotherapy and investigational agents before entering this study
- Sexually active patients must be willing to utilize one of the more effective birth control methods for 3 months after the T-cell infusion.
- Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent.
Treatment Exclusion Criteria:
- Pregnancy or lactation
- Uncontrolled infection
- Known HIV positivity
- Active bacterial, fungal or viral infection
- History of organ transplantation
- History of hypersensitivity reactions to murine protein-containing products OR presence of human anti-mouse antibody (HAMA) prior to enrollment (only patients who have received prior therapy with murine antibodies)